NCT06414915View on ClinicalTrials.gov

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

NSCLC

Interventions

DRUG

Surufatinib

250 mg, po, qd, q3w

DRUG

Tislelizumab

200mg, iv, q3w

All Listed Sponsors

lead

National Cancer Center, China

OTHER